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Stroke rate is markedly reduced after carotid 
endarterectomy by avoidance of protamine 
Michael C. Mauney, MD, Scott A. Buchanan, MD, W. Andrew Lawrence, BS, 
Andrew Bishop, BS, Kim Sinclair, MS, Thomas M. Daniel, MD, 
Curtis G. Tribble, MD, and Irving L. Kron, MD, Charlottespille, Va. 
Purpose: Postoperative neurologic injury remains asignificant risk of carotid endarterec- 
tomy. Mechanisms include embolization of debris and formation of thrombus on the 
newly endarterectomized surface. We hypothesized that the risk of postoperative 
neurologic injury would be lower in those patients who did not receive protamine for 
reversal of heparin anticoagulation. 
Methods: We reviewed 348 consecutive primary carotid endarterectomies p rformed since 
January 1, 1986, to determine the relationship between surgical outcomes and reversal of 
heparin anticoagulation. Patients undergoing additional simultaneous cardiovascular 
procedures were excluded. One hundred ninety-three patients received protamine after 
completion of the endarterectomy. The remaining 155 patients did not receive any 
protamine. 
Results: All patients in both groups urvived to discharge. There were no strokes in those 
patients who did not receive any protamine; however, the stroke rate in the protamine 
group was 2.6% (5 of 193), p < 0.045. The incidence of hematoma requiring 
reexploration was 1.0% (2 of 193) and 1.9% (3 of 155) in the protamine and no-protamine 
groups, respectively (p = NS). Intraoperative shunting was used more frequently in the 
no-protamine group (84% vs 67%, p < 0.001), and patch angioplasty was performed 
more frequently in the protamine group (35% vs 15%, p < 0.001). However, neither 
shunting not patching significantly influenced stroke rates. 
Conclusions: We conclude that carotid endarterectomy without reversal of heparin 
anticoagulation is associated with a reduced postoperative stroke rate without asignificant 
increase in morbidity rates. (J VAsc SURG 1995;22:264-70.) 
Cerebrovascular disease rcmains the third leading 
cause of death in the United States, accounting for 
500,000 strokes a year.1 Because half of all strokes are 
attributed to carotid artery bifurcation disease, ca- 
rotid endarterectomy (CEA) has become the most 
common peripheral vascular operation performed in 
the United Stares. Despite significant improvements 
in patient selection and perioperative management, 
however, postoperative stroke remains a potentially 
devastating complication for 2% to 4% of patients 
undergoing CEA. 1-3 
The most likely mechanism of perioperative 
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stroke is cerebral embolization of platelet aggregates 
and thrombi from the operative site. In a recent 
review of more than 3000 CEAs, Riles et al. 4 
attributed almost half of the perioperative strokes to 
thromboembolic events, one half of which were 
identified in the operating room or recovery room. 
Several strategies for minimizing stroke after CEA 
have evolved. Foremost among them is a meticulous 
technique that minimizes manipulation of the artery 
during dissection and achieves smooth margins at the 
endarterectomy site. Two of the most common 
techniques used at the University ofVirginia include 
intraoperative shunting to maintain perfusion pres- 
sures distal to the occluding clamps 5 and patch 
angioplasty to avoid compromising the vascular 
lumen.6, 7 
Until recently all the senior authors administered 
protamine to reverse administration of systemic 
heparin on completion of the endarterectomy. How- 
ever, after a major stroke occurred in a patient after 
a routine CEA in 1991, one senior author began to 
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withhold protamine administration i an effort to 
prolong the period of heparin anticoagulation a d 
reduce the risk of thrombus formation and embo- 
lization during the immediate postoperative p riod. 
Avoidanoe of protamine has now become routine for 
all the senior authors after CEA. Since that time there 
have been no strokes in patients who did not receive 
protamine. This study was undertaken to test the 
'hypothesis that avoidance of protamine during CEA 
reduces the postoperative stroke rate. 
METHODS 
We reviewed the medical records of all patients 
undergoing primary CEA at the University of 
Virginia since January 1, 1986. All patients under- 
going concomitant cardiovascular p ocedures were 
excluded because of differences in anticoagulation 
protocol. All operations were performed by one of 
three faculty members of the Section of Vascular 
Surgery. Preoperative variables recorded were age, 
sex, symptomatic status, operative status (elective vs 
urgent/emergency), anddegree of contralateral ob- 
struction (as determined by preoperative angiogra- 
phy results). Intraoperative ariables included route 
of anesthesia delivery, use of a shunt, and use of patch 
angioplasty. After operation, a neurologic deficit was 
defined as a new unilateral sensory or motor deficit 
attributable to the operative side that persisted for 
greater than 24 hours. Focal deficits lasting less than 
24 hours were listed as transient ischemic attacks 
(TIAs). Focal sensory deficits attributable to man- 
dibular nerve injury or hypoglossal nerve injury were 
not included as deficits. Postoperative h ck hemato- 
mas were classified as those requiring reexploration. 
Standard operative procedure included the ad- 
ministration of 100 U/kg heparin intravenously after 
dissection of the carotid artery. Activated clotting 
times were not monitored. All senior authors fol- 
lowed the endarterectomy technique described by 
Thompson and Talkington. 8 Use of patch angio- 
plasty and intraoperative shunting varied according 
to the senior surgeon's preference. Intraoperative 
stump p ressures were occasionally recorded by two 
surgeons to identify patients requiring intraoperative 
shunting. The third author routinely performed 
shunting on all of bis patients. Both on-table 
angiography and Doppler scanning were occasionally 
used. Before July 1991 administration f protamine 
sulfate in 1 mg/kg doses was routine. However, after 
a stroke occurred uring an uncomplicated CEA, one 
of the senior authors routinely began to withhold 
protamine administration. This approach as now 
become routine for all three senior authors. After 
operation all patients were admitted to the surgical 
intensive care unit for hourly neurologic and cardio- 
vascular monitoring and treatment before being 
transferred to a routine surgical bed. Systemic blood 
pressure was maintained above 120 mm Hg with 
careful administration f intravenous crystalloid and 
kept below 160 mm Hg with either intravenous 
nitroprusside or hydralazine. All patients received 
aspirin before operation and continued to receive 
aspirin after operation. No patients received heparin 
or protamine after operation. All patients had 
Jackson-Pratt drains (Baxter Healthcare, Inc., Deer- 
field, Ill.) placed that were removed on postoperative 
day 1. 
Statistics. Differences between groups of pa- 
tients were compared by use of normal approxima- 
tion of proportions. Groups were considered signifi- 
cantly different ifp < 0.05. A log linear analysis with 
shunting, patching, and administration fprotamine 
was used to predict he best model of stroke. 
RESULTS 
All 348 patients survived to discharge. The 
perioperative stroke rate was 1.4% (5/348), and the 
TIA rate was 1.4% (5 of 348). All five patients with 
stroke were found to have neurologic deficits appar- 
ent on awakening from general anesthesia, which 
necessitated emergency reexploration. The clinical 
course of all five patients who had a stroke after 
endarterectomy is summarized in Table I. Four of the 
five patients were found to have thrombosis at the 
endarterectomy site without evidence of technical 
flaws such as intimal flaps, stenoses, or kinking. The 
remaining patient had no identifiable cause of stroke. 
There were no delayed-onset strokes. Five patients 
required reexploration for neck hematomas (1.4%). 
All patients were neurologically intact before and 
after reexploration. One patient had development of
bleeding on postoperative day 1 associated with a 
significant period of systolic hypertension. The re- 
maining hematomas were diagnosed within the first 
few hours after surgery. Two patients underwent 
reexploration immediately in the operating room 
after bleeding and vigorous coughing were noticed 
on extubation. The other patients were taken back to 
the operating room from the postoperative unit and 
underwent exploration under local anesthesia. He- 
matomas occurred in 2.2% (2 of 90) of patients 
undergoing patch angioplasty, one with Gore-tex ~
(1/62) and the other with facial vein (1/28) for 
hematoma r tes of 1.6% and 3.6% for the t-wo patch 
*Gore-tex is a trademark ofW.L.  Gore & Associates, Elkton, Md. 
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Table_ I. Preoperative indications, extent of disease, postoperative &ticks, and treatment of all 
patients have perioperative stroke after CEA 
Onset o B 
Preoperative Postoperative deficit/diagnostic Findings at 
Patient H is to ry  arteriogram Shunted/patched deficits test obtained reexploration Procedure 
1 R-sided TIAs Moderate L Yes/no No R arm In postopera- Small thrombi n Primary closure 
stenosis movement nve unit/none CCA, none in 
I CA, no tech- 
nical flaws 
2 L amaurosis, L stenosis > 90% Yes/no R hemipa- In postopera- Large thrombus Thrombectomy, 
weak on R resis/speech tivc unit/A in CCAflCA, no PFGE angio- 
hestanoy gram > CCA technical f aws plasty 
occlusion 
3 R facial L ulcerated Yes/no R hemi- In postopera- Thrombus, no Thrombectomy, 
paresthesias plaques paresis tive unit/A technical flaws primary closure 
gram > ICA 
occlusion 
4 R-sided TIAs Bilateral ulcerated Yes/no R leg weak In OR/on-table No thrombus, no Primary closure 
plaqucs A-gram > technical flaws 
clean 
5 Asymptomatic Bilateral 90% ste- Yes/no L leg weak In OR/none Complete ICA Thrombectomy 
pod 6 L CEA nosis thrombosis, no and PTFE an- 
technical flaws gioplasty 
R, Right; L, leit; CCA, common carotid artery; A-gram, arteriogram; OR, operating room; pod 6, postoperative day 6. 
materials, respectively (p = 0.58). No patient re- 
quired transfusion of blood products after operation. 
Regarding intraoperative r versal of heparin an- 
ticoagulation, 193 patients received protamine, and 
155 patients did not receive protamine. Table II 
displays the demographic, intraoperative, and post- 
operative variables for all patients undergoing CEA 
either with or without protamine administration. 
There were no significant differences between the 
two groups in terms ofurgcnt or emergency nced for 
surgery, anesthetic delivery, or contralateral disease. 
However, patients who received protamine were 
slightly youngcr, had fewer symptoms, and were 
more likely to be women. There »vere differences in 
surgical technique as weil; patients receiving prot- 
amine were more likely to have undergone intraop- 
erative patch angioplasty with polytetrafluoroethyl- 
ene (PTFE) patches and less likely to have undergone 
shunting than those patients not receiving prot- 
amine. 
Table III documents the postoperative outcomes 
for all patients on the basis of whether they reccived 
protamine. There were no significant differences in 
rates of rcexploration for hcmatoma or TIAs. Most 
striking, however, was the observation that all five 
strokes occurred in those patients who received 
protamine. By approximation ofproportions, the use 
of protamine was associated with a significantfy 
higher perioperative stroke rate when compared with 
padents who did not receive protamine. Table IV 
illustrates that neither shunting nor patch angioplasty 
itself was associated with an increased risk of stroke. 
Similarly, the stroke rate did not differ among the 
three senior authors. Log linear analysis of the data in 
Table V revealed that the combination of shunting, 
no patching, and protamine administration was the 
best predictor of stroke. 
DISCUSSlON 
CEA has been widely performed for decades. 
Recently, well-organized, prospective randomized 
trials have reported the efficacy of CEA over medical 
therapy for patients with symptoms. 9'1° New data 
seem to suggest that selected symptom-frce patients 
may benefit from CEA as well. n These findings may 
weil lead to an even greater use of CEA for the 
treatrnent of cerebrovascular disease. The stroke 
council of the American Heart Association recom- 
men& that the combined morbidity and mortality 
rate after CEA for patients with and without symp- 
toms should not exceed 5% and 3%, respectively. ~2
Fortunately, most active vascular surgeons who 
routinely perform CEA can report similarly low 
morbidity and mortality rates. Nevertheless, asmore 
symptom-free patients undergo CEA, efforts must 
continue to reduce the risk of perioperative stroke. 
In our study we found an overall stroke rate of 
1.4% with no deaths, consistent with results oflarger 
series on CEA morbidity and death, la Even in those 
patients who received protamine, the stroke rate was 
still an acceptably low 2.6%. However, as we 
expected, we found a 0% stroke rate in those patients 
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Table II. Demographic, preoperative, and postoperative data for patients undergoing CEA either 
with or without protamine administration, p values by approximation of proportions 
No protamine (n = 155) Protamine (n = 193) p Values 
Average age (yrs.) 68.8 65.9 p < 0.03 
Men (%) 70.3 59.1 p < 0.001 
Preoperative symptoms (%) 85.2 75.1 p = 0.021 
Operative classification (%) 
Elective 94.8 95.9 NS 
Urgent/emergency 5.2 4.1 NS 
Contralateral diseäse (%) 
Stenosis > 90% 9.0 10.9 NS 
Total occlusion 9.7 6.2 NS 
Anesthesia (%) 
General 97.4 99.0 NS 
Local 2.ö 1.0 NS 
Patch angioplasty (%) 
PTFE 6.5 26.9 p - 0.000 
Facial vein 6.5 6.2 NS 
Other rein 1.9 1.0 NS 
Shunted uring operation (%) 83.9 69.0 p < 0.001 
Table III. Comparison of postoperative outcomes after CEA with and without protamine, p values 
by approximation of proportions 
Clinical outcomes No protarnine Protamine 
(%) (n = 155) (n = 193) p values 
Perioperative stroke 0.0 (0/155) 2.6 (5/193) p = 0.045 
TIA 1.9 (3/155) 1.0 (2/193) p = 0.480 
Hematoma requiring reexploration 1.9 (3/155) 1.0 (2/193) p = 0.480 
Table IV. Stroke rate as determined by use of shunts, patch angioplasty, and individual surgeons, p 
values by approximation of proportions 
Shunt No shunt Patch No patch 
Author 1 Author 2 Author 3 
n = 260 n = 88 n = 90 n = 258 (n = 243) (n = 61) (n = 44) 
Stroke rate 1.9% 0% 0% 1.9% 1.2% 1.6% 2.2% 
p Value NS,p - 0.194 NS, p = 0.184 NS, p > 0.60 
Table V. Stroke rates as determined by use of protamine, shunts, and patch angioplasty 
Not patched Patched 
Shunted Not shunted Shunted Not shunted 
Protamine 6.1% (n = 82) 0% (n = 45) 0% (n = 48) 0% (n = 18) 
No protamine 0% (n = 116) 0% (n = 16) 0% (n = 14) 0% (n = 9) 
who did not receive protamine at the completion 
of the endarterectomy, a difference that was statisti- 
cally significant. Although the combined neurologic 
events rate (cerebrovascular accident and TIA) were 
not sign, ificantly different between the two groups, 
we strongly believe that the reduction in morbidity 
associated with stroke versus TIAs is a better 
endpoint for clinical outcomes after CEA. Further- 
more, this reduction i  stroke rate was not associated 
with any significant increase in morbidity related to 
wound hematomas. Our hematoma r te of 1.9% is 
the lowest reported in a series of patients not re- 
ceiving protamine. Previous reports of patients 
undergoing CEA without protamine cite reexplora- 
tion rates for hematoma of 4.5% to 6.5%, 14,1~ this 
latter study also routinely drained patients who did 
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not receive protamine. Hematoma rates for patients 
receiving protamine range from 1.9% to 2.5%. lsqr 
Other differences between the protamine and 
no-protamine groups were found. The patients 
receiving no protamine were slightly older, more 
likely to have symptoms, and less likely to be men. 
One could argue that the frst two differences make 
the 0% stroke rate for the no-protamine group even 
more significant. Perhaps more important, however, 
there were differences in intraoperative t chnique 
between the groups. The patients receiving prot- 
amine were less likely to undergo shunting and more 
likely to have undergone patch angioplasty with 
PTFE. 
Did these differences in technique account for the 
different stroke rates between the protamine and 
no-protamine groups? We do not believe so for 
several reasons. First, Table IV shows, by the same 
statistical analysis as was used in Table III, that 
regardless ofprotamine administration, patients who 
underwent shunting did not have a statistically 
different stroke rate compared with patients who did 
not undergo shunting. The same observation was 
made when the issue of whether patients underwent 
patch angioplasty was examined. Second, the mecha- 
nism ofstroke in four offive patients clearly was acute 
thrombosis on the basis of the operative findings at 
the time of reexploration. There were no technical 
flaws identified in any of the endarterectomies. Table 
V indicates that all strokes occurred in patients who 
underwent shunting, did not undergo patch angio- 
plasty, and received protamine. More important, 
shunting and avoidance of patch angioplasty were 
not associated with any strokes as long as protamine 
was not given. We conclude that the patient under- 
going CEA with intraoperative shunting and no 
patch angioplasty may have a higher thrombogenic 
potential but that avoiding reversal of heparin 
anticoagulation with protamine significantly de- 
creases these patients' risk of stroke. 
Heparin has many mechanisms of action be- 
yond anticoagulation that could potentially minimize 
stroke in a postendarterectomy environment. Hepa- 
rin is a strongly charged glycosaminoglycan that 
displays a high protein binding potential. Heparin 
binding proteins have been identified on platelets, 
endothelial cells, monocytes, and neutrophils) 8 Po- 
tentially beneficial effects include decreased platele t 
adhesion to collagen, 19 decreased platelet activation 
and thromboxane r lease, 2° and decreased endothe- 
lial release of endothelin-1. 21 During the postisch- 
emic phase of reperfusion, heparin may also benefit 
neuronal cell survival by increasing plasma superox- 
idc dismutase activity and reducing free radical 
in jury.  22 Endothelial damage ffom ischemia and 
reperfusion may be minimized by several antiinflam- 
matory effects of heparin including attenuation of 
tumor necrosis factor-induced endothelial toxicity 
after ischemia and reperfusion, 23 antagonism of 
histamine and bradykinin, 24and inhibition of com- 
plement activation. 2sGiven these beneficial effects of 
heparin, it is logical to hypothesize that reversal of 
heparin with protamine in the thrombogenic envi- 
ronment of the postendarterectomy carotid artery 
could increase the potential for stroke by increasing 
the chance of thrombus formation, embolization, 
and endothelial injury. In addition protamine has 
been shown to directly injure canine coronary artery 
endothel ial  cells 26 and is associated with well- 
described, potentially lethal anaphylactic reactions. 27
Could these strokes have been prevented? As 
already mentioned, on-table completion studies were 
only occasionally performed. On-table angiography 
or ultrasonography as been recommended as a 
means to detect clinically significant defects in the 
freshly endarterectomized artery. 28 However, we 
believe that routine use of such imaging modalities 
may incur unnecessary cost and risk to the patient. 
Furthermore, the ability of such procedures toreduce 
perioperative stroke rates has been challenged by a 
recent review by Jain et al.29 They found a cumulative 
stroke rate of 2.0% in 10 series of patients receiving 
completion angiography compared with a 2.2% 
stroke rate in 430 of their own patients who clid 
not receive any completion studies. No evidence of 
technical flaws such as intimal flaps were found in any 
of our patients undergoing reexploration for new 
neurologic deficits. Therefore we do not believe that 
these strokes could have been prevented by any 
intraoperative radiographic studies. 
In conclusion, we recognize the limitations ofthis 
study as those related to any single-institution, 
retrospective r view of an operative procedure with 
several surgeon-dependent t chniques. The relatively 
small number of patients and the infrequent occur- 
rence of postoperative stroke limits the statistical 
analysis. Nevertheless, we have performed 155 CEAs 
without he use of protamine and have not encoun- 
tered any postoperative strokes, compared with a 
2.6% stroke rate in those patients who did receive 
protamine. We believe this difference is real but 
concede that larger numbers of patients from mul- 
tiple institutions are needed to strengthen our 
argument. As more patients undergo CEA, reduction 
of the already low risk ofperioperative stroke must be 
pursued. Avoidance of protamine is a simple, safe 
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technique that has made the practice o f  CEA at the 
University o f  Virginia safer. 
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D ISCUSSION 
Dr. Bertram L. Smith (Dallas, Texas). This is an 
intcresting study that attempts to analyze one of the 
causative factors of stroke after CEA. Although the authors 
agree that the sources of perioperative stroke are multiple, 
namely cerebral ischemia, embolization that occurs during 
operation, and thrombus formation at the endarterectomy 
site, the specific ause studied, in retrospect, is the effect of 
neutralization of heparin by protamine sulfatc given at the 
completion of endarteretomy: patients who received no 
protamine had no strokes versus 2% to 6% of patients 
receiving protamine. 
Although it is weil kaaown that the heparin-protamine 
complex may cause numerous physiologic hanges uch as 
leukopenia, thrombocytopenia, complement activation, 
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and pulmonary vasoconstriction, especially when the prot- 
amine is given rapidly, it is less clear whether protamine 
causes increased platelet adhesiveness and thrombosis of 
endarterectomized surfaces when combined with heparin. 
Moreover it is undocumented in this series that any of the 
known physiologic sequelae of heparin-protamine i terac- 
tion occurred in those patients who had perioperative 
stroke. Therefore it is difficult to credit the absence of 
protamine to the absence of stroke in this series. 
Also there are other variables including carotid artery 
patching and shunting that may have had some bearing on 
postoperative r sults. 
It is interesting, however, that no strokes occurred in 
those patients who received no protamine. Obviously 
further investigation is needed. 
It has been shown by several studies that thromboxane 
is the primary mediator of the pulmonary vasoconstrictive 
thrombocytopenic reaction that occurs in up to 5% to 15% 
of patients receiving protamine heparin reversal. Blocking 
thromboxane synthetase will diminish the physiologic 
reaction that occurs. 
Because all your patients were receiving aspirin, what 
caused the "breakthrough t rombosis" that occurred in 
those patients who had stroke? 
Because the patients who had stroke had neurologic 
deficits on awakening from anesthesia, how do you exclude 
intraoperative embolization as a cause? 
How many hematomas occurred that did not require 
exploration? Do you believe that residual blood in the 
wound increases the risk of late synthetic patch infection? 
Dr. Michael C. Mauney. With regard to your first 
question about the mechanism of thrombosis, given that 
patients were receiving aspirin, despite inhibition of 
thromboxane production, there must have been enough 
stimulus for platelet activation, either from the injured 
endothelial surface or possibly decreased synthesis of the 
antiplatelet prostaglandin prostacyclin. Eren though we 
did not document the presence ofany systemic effects of the 
heparin-protamine complex you summarized, they do not 
necessarily have to be present for the prothrombotic effects 
we cite to occur. With regard to the mechanism of stroke, 
all patients with new neurologic deficits underwent imme- 
diate reexploration. Partial or complete thrbombosis at the 
endarterectomy site was found in four of the patients 
without any evidence of intimal flaps, kinks, or arterial 
lumen compromise We cannot rule out thromboembolism 
from excessive dissection, clamp placement and removal, or 
shunt insertion as a cause of stroke in the other patient. 
With regard to your third question, we were not able to 
thoroughly determine the presence or absence of mild 
hematomas not requiring reexploration because of the 
retrospective nature of the study and lack ofdocumentation 
in some cases. Out impression is that withholding prot- 
amine is not associated with any higher incidence ofminor 
hematomas. Of course we are concerned about any 
hematoma in the presence of synthetic patches and have 
been fortunae not to have seen this problem so far. 
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